| abstract |
An inhalable dry powder comprising (A) as the only active ingredient, formoterol, or a pharmaceutically acceptable salt or solvate thereof, or solvate of said salt; and (B) a pharmaceutically acceptable particulate diluent or carrier in an amount of 400 µg to 5,000 µg per µg of (A), wherein the maximum diameter of the particulate diluent or carrier is 300 µm; for use in the treatment of chronic obstructive pulmonary disease. |